
Nezam Ibrahim Altorok

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9186797/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. Annals of the Rheumatic Diseases, 2015, 74, 1612-1620.	0.9	148
2	Genomeâ€Wide DNA Methylation Patterns in Naive CD4+ T Cells From Patients With Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2014, 66, 731-739.	5.6	147
3	Endothelial dysfunction in systemic sclerosis. Current Opinion in Rheumatology, 2014, 26, 615-620.	4.3	77
4	Epigenetics, the holy grail in the pathogenesis of systemic sclerosis. Rheumatology, 2015, 54, 1759-1770.	1.9	73
5	Identification of potential genomic biomarkers for Sjögren's syndrome using data pooling of gene expression microarrays. Rheumatology International, 2015, 35, 829-836.	3.0	55
6	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. Journal of Scleroderma and Related Disorders, 2018, 3, 249-252.	1.7	33
7	Epigenetics and systemic sclerosis. Seminars in Immunopathology, 2015, 37, 453-462.	6.1	27
8	Epigenetics in the pathogenesis of systemic lupus erythematosus. Current Opinion in Rheumatology, 2013, 25, 569-576.	4.3	26
9	Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: A systematic review. Seminars in Arthritis and Rheumatism, 2014, 43, 536-541.	3.4	19
10	Successful Treatment of ANCA-Associated Vasculitis in the Setting of Common Variable Immunodeficiency Using Rituximab. American Journal of Therapeutics, 2016, 23, e1239-e1245.	0.9	11
11	Epigenetics and systemic sclerosis: An answer to disease onset and evolution?. European Journal of Rheumatology, 2020, 7, 147-156.	0.6	11
12	Evaluation of topical econazole nitrate formulations with potential for treating Raynaud's phenomenon. Pharmaceutical Development and Technology, 2019, 24, 689-699.	2.4	8
13	Diffuse Soft-Tissue Calcinosis. New England Journal of Medicine, 2015, 373, 173-173.	27.0	6
14	The isolation and characterization of systemic sclerosis vascular smooth muscle cells: enhanced proliferation and apoptosis resistance. Journal of Scleroderma and Related Disorders, 2016, 1, 307-315.	1.7	6
15	Mycobacterium Avium Complex Septic Arthritis in a Patient Treated by Infliximab. American Journal of Therapeutics, 2016, 23, e1222-e1225.	0.9	6
16	Successful Treatment of Central Nervous System Vasculitis Associated with Relapsing Polychondritis With Cyclophosphamide. American Journal of the Medical Sciences, 2017, 353, 495-497.	1.1	6
17	Ultrasound-mediated topical delivery of econazole nitrate with potential for treating Raynaud's phenomenon. International Journal of Pharmaceutics, 2020, 580, 119229.	5.2	6
18	Genome-wide DNA methylation pattern in systemic sclerosis microvascular endothelial cells: Identification of epigenetically affected key genes and pathways. Journal of Scleroderma and Related Disorders, 2022, 7, 71-81.	1.7	4

#	Article	IF	CITATIONS
19	Epigenetics and systemic sclerosis: An answer to disease onset and evolution?. European Journal of Rheumatology, 2020, 7, S147-S156.	0.6	4
20	Successful treatment of antisynthetase syndrome presenting as rhabdomyolysis with rituximab. Rheumatology International, 2018, 38, 1125-1130.	3.0	3
21	Adalimumab-Associated Hemorrhagic Pericarditis. American Journal of Therapeutics, 2020, 27, e630-e632.	0.9	2
22	Genital lesions and acute urinary retention. Cleveland Clinic Journal of Medicine, 2011, 78, 151-152.	1.3	1
23	Leflunomide-Associated Pancytopenia. American Journal of Therapeutics, 2023, 30, e563-e565.	0.9	1